Autologous Stem Cell Transplantation for Children With Renal Tumors, and Adults With Wilms Tumor: Retrospective Analysis of the Japanese Transplant Registry Unified Management Program.
Autologous Stem Cell Transplantation for Children With Renal Tumors, and Adults With Wilms Tumor: Retrospective Analysis of the Japanese Transplant Registry Unified Management Program.
复制标题
儿童肾肿瘤和成人肾母细胞瘤的自体干细胞移植：日本移植登记统一管理计划的回顾性分析。
DOI：
10.1097/mph.0000000000001779
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Matsumoto K
中科院分区：
文献类型：
--
作者：
Kobayashi R;Inoue M;Takahashi Y;Kikuta A;Ogawa A;Koga Y;Koh K;Hashii Y;Hara J;Kato K;Tabuchi K;Matsumoto K
背景：几乎所有肾肿瘤儿科患者都被诊断为肾母细胞瘤（维尔姆斯瘤）、透明细胞肉瘤或恶性横纹肌样瘤。治疗方法的选择对于复发和难治性肾母细胞瘤患者非常重要。此外，与肾母细胞瘤相比，肾脏透明细胞肉瘤（CCSK）和肾脏恶性横纹肌样瘤（MRTK）的预后较差。因此，有时会选择干细胞移植 (SCT) 来治疗这些肿瘤。 患者和方法：作者以 84 名肾母细胞瘤、CCSK 和 MRTK 患者为对象，这些患者在 1992 年至 2014 年间接受了首次自体 SCT，并在日本移植登记统一管理计划系统中注册。作者回顾性分析了SCT数据的生存率。结果：肾母细胞瘤、CCSK和MRTK的五年总生存率分别为72.4%±6.3%、46.8%±13.8%和36.4%±14.5%。 5年无事件生存率分别为64.9%±6.7%、35.7%±12.8%和27.3%±13.4%。 5年复发率分别为25.3%±11.4%、46.2%±28.4%、60.0%±43.1%。结论：虽然肾母细胞瘤的生存率较高，但CCSK和MRTK的生存率较差。
Background:Almost all pediatric patients with renal tumors are diagnosed with nephroblastoma (Wilms tumor), clear cell sarcoma, or malignant rhabdoid tumor. The choice of treatment is important for relapsed and refractory patients with nephroblastoma. Furthermore, clear cell sarcoma of the kidney (CCSK) and malignant rhabdoid tumor of the kidney (MRTK) have a poor prognosis compared with nephroblastoma. Thus, stem cell transplantation (SCT) is sometimes selected to treat these tumors.Patients and Methods:The authors targeted a total of 84 patients with nephroblastoma, CCSK, and MRTK who underwent a first autologous SCT between 1992 and 2014, and were registered in the Japanese Transplant Registry Unified Management Program system. The authors retrospectively analyzed the SCT data for survival rate.Results:Five-year overall survival rates for nephroblastoma, CCSK, and MRTK were 72.4%±6.3%, 46.8%±13.8%, and 36.4%±14.5%, respectively. The event-free survival rates at 5 years were 64.9%±6.7%, 35.7%±12.8%, and 27.3%±13.4%, respectively. The relapse rates at 5 years were 25.3%±11.4%, 46.2%±28.4%, and 60.0%±43.1%, respectively.Conclusion:Although the survival rate for nephroblastoma was relatively high, those of CCSK and MRTK were poor.